Last reviewed · How we verify

Fentanyl/Atropine/Succinylcholine

King Saud University · FDA-approved active Small molecule

This is a combination of three drugs used in anesthesia: fentanyl (opioid analgesic), atropine (anticholinergic), and succinylcholine (depolarizing neuromuscular blocker) that together provide analgesia, prevent vagal responses, and induce muscle paralysis.

This is a combination of three drugs used in anesthesia: fentanyl (opioid analgesic), atropine (anticholinergic), and succinylcholine (depolarizing neuromuscular blocker) that together provide analgesia, prevent vagal responses, and induce muscle paralysis. Used for Induction and maintenance of general anesthesia, Facilitation of endotracheal intubation, Analgesia and sedation during surgical procedures.

At a glance

Generic nameFentanyl/Atropine/Succinylcholine
SponsorKing Saud University
Drug classAnesthetic combination (opioid + anticholinergic + neuromuscular blocker)
TargetMu-opioid receptor (fentanyl); muscarinic acetylcholine receptors (atropine); nicotinic acetylcholine receptors at neuromuscular junction (succinylcholine)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Fentanyl acts as a potent mu-opioid receptor agonist to provide analgesia and sedation. Atropine blocks muscarinic acetylcholine receptors to prevent bradycardia and excessive salivation caused by succinylcholine. Succinylcholine acts as a depolarizing agent at the neuromuscular junction, causing sustained depolarization that leads to muscle paralysis necessary for intubation and mechanical ventilation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: